Benefit-Risk Assessment Framework Moves Toward Global Harmonization

The Pharmaceutical Research and Manufacturers of America is transferring its framework for risk-benefit assessment to the Centre for Innovation in Regulatory Science Ltd. for further development on the road to harmonization of how companies and regulators evaluate drugs.

The transfer, announced Jan. 30, helps consolidate efforts to bring consistency to benefit-risk assessments across the globe. London-based CIRS, whose...